Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

• DOI: 10.1007/s40744-022-00445-w
• Publication Date: 2022-04-09T10:02:50Z
• Authors: Lihi Eder; Hans-Peter Tony; Satish Odhav; Eva Galindez Agir...; Mariusz Korkosz; Sergio Schwartzman; Aubrey Trevelin S...; Amanda M. Gellett; So Young Park; Clinton C. Bertram; Alexis Ogdie
• Keywords: Ixekizumab

Differences in psoriatic arthritis (PsA) treatment response between sexes for ixekizumab, an interleukin-17A antagonist, are largely unexplored. This analysis used data from randomized clinical trials (RCTs) evaluating ixekizumab to study differences male and female patients with PsA.We pooled enrolled SPIRIT-P1 SPIRIT-P2 (NCT01695239 NCT02349295, respectively), phase 3 RCTs every 4 2 weeks active PsA. Subgroups of were defined by sex (male, female). Efficacy was measured the proportion achieving American College Rheumatology 20%/50%/70% improvement criteria (ACR20/50/70), minimal disease activity or very low (MDA/VLDA), Disease Activity Index Psoriatic Arthritis (DAPSA) scores representing (LDA) remission through week 156. Changes baseline components above measures also assessed 156.Compared at baseline, older, had higher body mass index lower C-reactive protein levels, worse tender joint count, Health Assessment Questionnaire Disability Index, Leeds Enthesitis scores. Through 156, all arms rates than analyzed composite (ACR20/50/70; MDA/VLDA; DAPSA LDA/remission), significant observed multiple timepoints both arms. Female smaller numeric changes measures' individual components.Compared patients, greater ACR20/50/70, MDA/VLDA, LDA/remission numerically larger improvements these components, although significance is unclear. Continued efforts understand may provide insights that can help optimize decision making.ClinicalTrials.gov identifiers, NCT01695239 NCT02349295.